Literature DB >> 14583576

Anticardiolipin, anti-beta(2)-glycoprotein I and antiprothrombin antibodies in black South African patients with infectious disease.

S Loizou1, S Singh, E Wypkema, R A Asherson.   

Abstract

OBJECTIVES: To investigate IgG, IgM, and IgA, antiphospholipid antibodies (aPL), against cardiolipin (aCL), beta(2)-glycoprotein I (anti-beta(2)GPI), and prothrombin (anti-PT), in black South African patients with infectious disease. Unlike patients with systemic lupus erythematosus (SLE) and the antiphospholipid syndrome (APS), raised levels of aPL in infectious diseases are not usually associated with thrombotic complications. PATIENTS AND METHODS: Serum samples from 272 patients with a variety of infectious diseases (100 HIV positive, 112 leprosy, 25 syphilis, 25 malaria, and 10 HCV patients) were studied and compared with autoantibody levels in 100 normal controls. All three aPL were measured using commercial enzyme linked immunosorbent assay (ELISA) kits.
RESULTS: Raised levels of all three aPL were found in all patient groups studied: aCL in 7%, anti-beta(2)GPI in 6%, and aPT in 43% of 100 HIV patients, in 29%, 89%, and 21% of 112 patients with leprosy, in 8%, 8%, and 28% of 25 patients with syphilis, in 12%, 8%, and 28% of 25 patients with malaria, and in 20%, 30%, and 30% of 10 HCV patients studied, respectively.
CONCLUSIONS: The prevalence of aCL and anti-beta(2)GPI in black South African HIV positive patients, or those with syphilis, malaria, or hepatitis C virus is lower than reported for mixed race or white populations. aPT were the most prevalent aPL detected in these patient groups, except in patients with leprosy, for whom anti-beta(2)GPI was the most prevalent, and where the spectrum of aPL was similar to that seen in patients with SLE and APS.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14583576      PMCID: PMC1754364          DOI: 10.1136/ard.62.11.1106

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  31 in total

Review 1.  Catastrophic antiphospholipid syndrome: clues to the pathogenesis from a series of 80 patients.

Authors:  R A Asherson; R Cervera; J C Piette; Y Shoenfeld; G Espinosa; M A Petri; E Lim; T C Lau; A Gurjal; A Jedryka-Góral; H Chwalinska-Sadowska; R J Dibner; J Rojas-Rodríguez; M García-Carrasco; J T Grandone; A L Parke; P Barbosa; C Vasconcelos; M Ramos-Casals; J Font; M Ingelmo
Journal:  Medicine (Baltimore)       Date:  2001-11       Impact factor: 1.889

2.  Antibodies to beta2-glycoprotein I--a specific marker for the antiphospholipid syndrome.

Authors:  J Guerin; C Feighery; R B Sim; J Jackson
Journal:  Clin Exp Immunol       Date:  1997-08       Impact factor: 4.330

3.  High prevalence of anticardiolipin antibodies in hepatitis C virus infection: lack of effects on thrombocytopenia and thrombotic complications.

Authors:  M Harada; Y Fujisawa; S Sakisaka; T Kawaguchi; E Taniguchi; M Sakamoto; S Sumie; K Sasatomi; H Koga; T Torimura; T Ueno; K Gondo; H Yoshida; K Tanikawa; M Sata
Journal:  J Gastroenterol       Date:  2000       Impact factor: 7.527

4.  Cofactor dependence and isotype distribution of anticardiolipin antibodies in viral infections.

Authors:  H Guglielmone; S Vitozzi; O Elbarcha; E Fernandez
Journal:  Ann Rheum Dis       Date:  2001-05       Impact factor: 19.103

5.  Anti-phospholipid antibodies in HIV infection and SLE with or without anti-phospholipid syndrome: comparisons of phospholipid specificity, avidity and reactivity with beta2-GPI.

Authors:  C Petrovas; P G Vlachoyiannopoulos; T Kordossis; H M Moutsopoulos
Journal:  J Autoimmun       Date:  1999-11       Impact factor: 7.094

6.  Antiphosphatidylserine antibodies in patients with autoimmune diseases and HIV-infected patients: effects of Tween 20 and relationship with antibodies to beta2-glycoprotein I.

Authors:  C González; A Lestón; B García-Berrocal; A Sánchez-Rodriguez; J A Martín-Oterino; I Alberca; M Cordero; R Jorge; J A Navajo; J M González-Buitrago
Journal:  J Clin Lab Anal       Date:  1999       Impact factor: 2.352

7.  Reactivity to beta 2 glycoprotein I clearly differentiates anticardiolipin antibodies from antiphospholipid syndrome and syphilis.

Authors:  R R Forastiero; M E Martinuzzo; L C Kordich; L O Carreras
Journal:  Thromb Haemost       Date:  1996-05       Impact factor: 5.249

8.  Antiphospholipid antibodies in leprotic patients: a correlation with disease manifestations.

Authors:  A Elbeialy; K Strassburger-Lorna; T Atsumi; M L Bertolaccini; O Amengual; M Hanafi; M A Khamashta; G R Hughes
Journal:  Clin Exp Rheumatol       Date:  2000 Jul-Aug       Impact factor: 4.473

9.  Kaolin clotting time and dilute Russell's viper venom time distinguish between prothrombin-dependent and beta 2-glycoprotein I-dependent antiphospholipid antibodies.

Authors:  M Galli; G Finazzi; E M Bevers; T Barbui
Journal:  Blood       Date:  1995-07-15       Impact factor: 22.113

10.  Prevalence and significance of anticardiolipin, anti-beta2 glycoprotein I and anti-prothrombin antibodies in chronic hepatitis C.

Authors:  V Leroy; J Arvieux; M C Jacob; M Maynard-Muet; M Baud; J P Zarski
Journal:  Br J Haematol       Date:  1998-06       Impact factor: 6.998

View more
  17 in total

1.  Fluctuation in the Levels of Immunoglobulin M and Immunoglobulin G Antibodies for Cardiolipin and β2-Glycoprotein among Healthy Pregnant Women.

Authors:  Mohammed S Al-Balushi; Sidgi S Hasson; Elias A Said; Juma Z Al-Busaidi; Muna S Al-Daihani; Mohammed S Othman; Talal A Sallam; Mohammed A Idris; Moza Al-Kalbani; Nicholas Woodhouse; Ali A Al-Jabri
Journal:  Sultan Qaboos Univ Med J       Date:  2014-10-14

2.  High frequency of antiphospholipid antibodies in relapse of multiple sclerosis: a possible indicator of inflammatory-thrombotic processes.

Authors:  Tatiana Koudriavtseva; Giovanna D'Agosto; Chiara Mandoj; Isabella Sperduti; Paola Cordiali-Fei
Journal:  Neurol Sci       Date:  2014-05-22       Impact factor: 3.307

3.  Clinical and laboratory characteristics of children positive for antiphospholipid antibodies.

Authors:  Paola Giordano; Riccardina Tesse; Giuseppe Lassandro; Deborah Fracchiolla; Prudenza Ranieri; Antonella Lotito; Domenico De Mattia; Giovanni Carlo Del Vecchio
Journal:  Blood Transfus       Date:  2011-12-21       Impact factor: 3.443

Review 4.  Lucio's phenomenon: report of five cases.

Authors:  Pablo Finucci Curi; Julieta Solis Villaroel; Nora Migliore; Adriana Albertengo; María Laura Aquino; Federico Ceccato; Sergio Paira
Journal:  Clin Rheumatol       Date:  2014-05-27       Impact factor: 2.980

5.  A role for interleukin-5 in promoting increased immunoglobulin M at the site of disease in leprosy.

Authors:  Maria T Ochoa; Rosane Teles; Blake E Haas; Danny Zaghi; Huiying Li; Euzenir N Sarno; Thomas H Rea; Robert L Modlin; Delphine J Lee
Journal:  Immunology       Date:  2010-11       Impact factor: 7.397

6.  Reactivity profiles of broadly neutralizing anti-HIV-1 antibodies are distinct from those of pathogenic autoantibodies.

Authors:  Harvir Singh; Kevin A Henry; Sampson S T Wu; Andrzej Chruscinski; Paul J Utz; Jamie K Scott
Journal:  AIDS       Date:  2011-06-19       Impact factor: 4.177

7.  Antiphospholipid antibodies in HIV-positive patients.

Authors:  Liliana Galrão; Carlos Brites; Maria Luíza Atta; Ajax Atta; Isabella Lima; Fernanda Gonzalez; Fernanda Magalhães; Mittermayer Santiago
Journal:  Clin Rheumatol       Date:  2007-02-28       Impact factor: 2.980

8.  Lupus and leprosy: beyond the coincidence.

Authors:  F M Ribeiro; V E Gomez; E M N Albuquerque; E M Klumb; Y Shoenfeld
Journal:  Immunol Res       Date:  2015-02       Impact factor: 2.829

9.  Portal vein thrombosis in a patient with hepatitis C virus-related cirrhosis complicated with antiphospholipid syndrome.

Authors:  Yohei Kida; Etsuko Maeshima; Yoichi Yamada
Journal:  Rheumatol Int       Date:  2009-01-28       Impact factor: 2.631

10.  Clinical and serological correlates of antinucleosome antibodies in South Africans with systemic lupus erythematosus.

Authors:  M Tikly; T Gould; A A Wadee; E van der Westhuizen; B B N Mokgethwa
Journal:  Clin Rheumatol       Date:  2007-05-22       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.